The Impact of Ustekinumab Biosimilar on Therapeutic Strategies in Crohn's Disease: A Paradigm Shift?

C Bezzio; A Armuzzi

doi:10.1002/ueg2.12717

The Impact of Ustekinumab Biosimilar on Therapeutic Strategies in Crohn's Disease: A Paradigm Shift?

United European Gastroenterol J. 2024 Nov 30. doi: 10.1002/ueg2.12717. Online ahead of print.

Authors

C Bezzio^{1

2}, A Armuzzi^{1

2}

Affiliations

¹ IBD Unit, Gastroenterology Department, IRCCS Humanitas Research Hospital, Rozzano, Italy.
² Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.

PMID: 39614822
DOI: 10.1002/ueg2.12717

No abstract available

Keywords: IBD; anti‐IL12/23; anti‐IL‐23; biosimilars; costs; earlier treatment; inflammatory bowel disease; risankizumab; saving costs; sustainability.

Publication types

Editorial